A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.
producing a secreted CD40 agonist monoclonal antibody
producing IL-12, IL-15 and a chemokine
Product Concept: Tumor-specific delivery of potent immune cell recruitment & activating agents avoiding systemic toxicity
Product Concept: Tumor-specific delivery of CAR-T targets to enhance the efficacy and/or improve the safety profile of the cell therapy
Transgene payload packages including natural and synthetic tumor antigens
CAR T-cell targeting & activation
T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery.
Unlocking Cell Therapy
T-SIGn® therapeutics have the potential to be used in combination with CAR-T and other cell therapies to overcome their limitations from an efficacy and safety perspective in the solid tumor setting.
Our clinical studies are investigating the use of T-SIGn® therapeutics in the monotherapy setting, as well as in combination with other immuno-oncology agents to target specific solid tumor immune resistance mechanisms.